leadf
logo-loader
viewHumanigen, Inc.

Humanigen secures $72M offering to fund development of coronavirus treatment lenzilumab

The company offered 9.2 million shares, 1.2 million of which were part of an over-allotment option exercised by the underwriters

Coronavirus graphic
Lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody drug candidate, is being evaluated in an ongoing Phase III trial and was selected by the National Institutes of Health for its COVID-19 Big Effect Trial

Humanigen Inc (NASDAQ:HGEN) announced Tuesday that it completed a previously announced $72.8 million public offering of common stock meant to fund the development of its drug lenzilumab as a treatment for the coronavirus (COVID-19).

The company offered 9.2 million shares, 1.2 million of which were part of an over-allotment option exercised by the underwriters.

Humanigen plans to use the proceeds to advance the development of lenzilumab, a drug designed to treat what’s known as the cytokine storm, an overactive immune response to conditions such as COVID-19 that can cause inflammation, fatigue and, in severe cases, organ failure. 

READ: Humanigen prices underwritten public offering of 8 million shares to raise $68M as it preps for Nasdaq debut

JP Morgan and Jefferies acted as joint book-running managers for the offering, the company said. Bryan, Garnier & Co acted as the European lead manager and National Securities Corporation, Roth Capital Partners and HC Wainwright & Co acted as co-managers.

Lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody drug candidate, is being evaluated in an ongoing Phase III trial and was selected by the National Institutes of Health for its COVID-19 Big Effect Trial. 

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Humanigen, Inc.

Price: - -

OTCMKTS:HGEN
Market: OTCQB
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Humanigen chosen by National Institute of Health's upcoming coronavirus...

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of Health’s upcoming coronavirus trial. Durrant says lenz will be evaluated in the National Institute of Allergy and Infectious Diseases’...

on 07/31/2020

2 min read